Evidence Snapshot

Muscarinic acetylcholine receptor M1

CHEMBL2672 SINGLE PROTEIN Bos taurus

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:24Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:30 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2672

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Muscarinic acetylcholine receptor M1 as ChEMBL target CHEMBL2672, mapped to UniProt Q8WMX0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Muscarinic acetylcholine receptor M1

SINGLE PROTEIN · Bos taurus

As of 2026-09-13

ChEMBL target ID

CHEMBL2672

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q8WMX0

Muscarinic receptor M1

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Muscarinic acetylcholine receptor M1 matters

As of 2026-09-13

Muscarinic acetylcholine receptor M1 is reviewed as Muscarinic receptor M1 (UniProt Q8WMX0); the current evidence base includes 2 approved drugs, 35 compounds, and 9 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Muscarinic receptor M1

Muscarinic receptor M1 Sequence length is 139 aa.

Review this target as Muscarinic acetylcholine receptor M1, mapped to UniProt Q8WMX0. ChEMBL maps the protein component as Muscarinic receptor M1. Sequence length is 139 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q8WMX0 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 35 compounds, and 9 assays for this target. The dominant activity type is KI. CHEMBL21812 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL21812 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

2 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Muscarinic acetylcholine receptor M1 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q8WMX0, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

Total Compounds

Total Assays

Approved Drugs

KI: 39.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL21812	11.0	Ki	—
No preferred name CHEMBL21905	10.7	Ki	—
No preferred name CHEMBL297276	10.0	Ki	—
No preferred name CHEMBL558910	9.7	Ki	—
No preferred name CHEMBL296895	9.7	Ki	—